Thursday, March 12, 2009
Patrick Swayze: Still Fighting
He’s been on the losing end of a battle with pancreatic cancer, but in a recent interview Patrick Swayze insisted that he’s still holding his ground.
The 56-year-old actor told press, “It’s amazing to me that the tabloids such as the National Enquirer print such negative stories about me and my health when there are so many positive things going on in my life right now. I’ve started a new chemotherapy and, once again, I am one of the lucky ones with pancreatic cancer that is responding well to the treatment.”
He even has a new puppy. “There is a brand new, 12-week-old, Rhodesian Ridgeback puppy named Kumasai in my life who is gorgeous and already showing that he will be one special dog. I am starting work on my new book, in addition to enjoying the fantastic response from everyone on my A&E series The Beast.”
Swayze added, “I hope in the future, the press will think twice about printing inaccuracies and painting an unpleasant picture when I have so much to be thankful for at this time.”
Article Pictures (Click to enlarge):
Photo Credit: FlynetOnline.com
Bookmark this Story | Share with a Friend
posted by at 07:24 AM
View all articles authored by: Jane
related categories ♥ celebrities ♥ patrick swayze ♥ celebrity medical
Link to this Story
COMMENTS
Pfizer Hopes To Keep Sutent Successes Coming
Melinda Peer, 03.13.09, 03:50 AM EDT
Company’s drug to treat pancreatic cancer proves encouraging in a late-stage trial.
Pfizer Inc.
03/13/2009 4:01PM ET$14.54$0.523.71%
1 day3 mo1 yearAdvanced
At A GlanceChartNewsPeople
BATS Real-Time Market Data by XigniteResults from a late-stage Pfizer trial studying the effectiveness of Sutent in stemming the advancement of a rare pancreatic cancer were so encouraging that the company called it quits and extended the treatment to placebo-popping patients.
Under the recommendation of an independent data monitoring committee, Pfizer (nyse: PFE - news - people ) ended the study early because patients taking Sutent saw the disease’s progression halted for longer than those receiving a placebo and other supportive treatment. Current treatment options for the unusual cancer, with five to 10 annual cases per million people worldwide
Posted by on 03/14 at 02:11 AM
This marks the second time that Pfizer has halted a late-stage trial of Sutent because of positive results. The drug is currently approved to treat renal cell carcinoma, a type of kidney cancer, and as a backup treatment for rare tumors found in the gastrointestinal tract.
“We are delighted by these findings, which demonstrate that Sutent provides a benefit for patients with advanced well-differentiated pancreatic islet cell tumors--a rare cancer with limited treatment options,” said Mace Rothenberg, a senior vice president in Pfizer’s oncology division.
Posted by on 03/14 at 02:14 AM
Citigroup analyst John Boris said the news gives minimal upside to his current Sutent estimates, which are based on approval for Sutent’s use in treating larger tumor types. “Pfizer is examining multiple indications for Sutent, which would provide greater marketing opportunities than pancreatic islet tumors.” He said that these include the treatment of various stages of breast cancer, and late-stage programs for lung, colorectal and prostate cancers.
Boris estimates that Sutent sales will increase by 21.0% year over year, to $1.0 billion, in 2009. He maintains a “hold” rating on the company, citing declining sales volumes, a limited late-stage pipeline and expected pressure from generic drugs.
Hope this is some help I had to send 3 comments because it was to long. Your in my prayer Patrick hope works for you.
Posted by on 03/14 at 02:16 AM
Page 1 of 1 pages
|
  >>Atom Feed |
Syndication
